Table 3 Socio-demographic and clinical factors associated with pre-ART loss to follow-up at GUH
Crude OR (95% CI) | Adjusted+OR (95% CI) | |||||
|---|---|---|---|---|---|---|
Variables | n total | n (%) | OR | 95% CI | OR | 95% CI |
Gender | 1089 | |||||
Male | 439 (40.3) | 1.01 | (0.78, 1.31) | 2.00 | (1.15, 3.46)* | |
Female | 650 (59.7) | 1.00 | 1.00 | |||
Age group | 1089 | |||||
15-24 | 176 (16.2) | 1.00 | 1.00 | |||
25-34 | 498 (45.7) | 0.59 | (0.41, 0.83)* | 0.80 | (0.40, 1.61) | |
35-44 | 283 (26.0) | 0.41 | (0.28, 0.61)* | 0.63 | (0.28, 1.41) | |
44+ | 132 (12.1) | 0.37 | (0.23, 0.61)* | 0.77 | (0.30, 2.00) | |
Marital status | 1089 | |||||
Never married | 190 (17.4) | 1.00 | 1.00 | |||
Married | 498 (45.7) | 0.62 | (0.43, 0.87)* | 0.39 | (0.19, 0.79)* | |
Divorced/separated | 319 (29.3) | 0.85 | (0.59, 1.23) | 1.18 | (0.57, 2.44) | |
Widow/er | 82 (7.5) | 0.54 | (0.31, 0.95)* | 0.54 | (0.18 , 1.68) | |
Educational status | 1089 | |||||
No education | 384 (35.3) | 1.00 | 1.00 | |||
Primary | 288 (26.4) | 1.03 | (0.75, 1.41) | 1.47 | (0.78, 2.77) | |
Secondary & above | 417 (38.3) | 0.67 | (0.50, 0.91)* | 0.88 | (0.48, 1.63) | |
Disclosure of HIV+ status | 1089 | |||||
To spouse/family members only | 616 (56.6) | 1.00 | 1.00 | |||
To relatives/friends only | 86 (7.9) | 0.90 | (0.55, 1.47) | 0.38 | (0.12, 1.19) | |
To spouse/family members & relatives/friends | 35 (3.2) | 1.14 | (0.56, 2.35) | 1.47 | (0.41, 5.32) | |
To no one | 352 (32.3) | 1.33 | (1.01, 1.75)* | 0.65 | (0.37, 1.14) | |
Place of residence | 1089 | |||||
Gondar | 796 (73.1) | 1.00 | 1.00 | |||
Out of Gondar | 293 (26.9) | 0.89 | (0.67, 1.18) | 1.07 | (0.61, 1.87) | |
History of TB treatment | 1044 | |||||
Yes | 222 (21.3) | 1.00 | 1.00 | |||
No | 822 (78.7) | 1.37 | (0.99, 1.89) | 0.73 | (0.39 , 1.35) | |
CD4 cell count/μl | 1076 | |||||
≤ 200 | 611(56.8) | 1.00 | 1.00 | |||
201-250 | 111(10.3) | 2.48 | (1.59, 3.87)* | 2.22 | (0.95, 5.19) | |
251-300 | 75 (7.0) | 2.38 | (1.41, 4.02)* | 2.64 | (1.05, 6.65)* | |
301-350 | 64 (5.9) | 5.75 | (3.37, 9.82)* | 5.21 | (1.94, 13.99)* | |
> 350 | 215 (20.0) | 10.76 | (7.52, 15.38)* | 12.10 | (6.33, 23.12)* | |
WHO stage | 1070 | |||||
Stage I | 257 (24.0) | 2.10 | (1.39, 3.15)* | 2.81 | (1.15, 6.91)* | |
Stage II | 194 (18.1) | 1.29 | (0.83, 2.01) | 1.75 | (0.69, 4.45) | |
Stage III | 446 (41.7) | 0.82 | (0.56, 1.21) | 1.72 | (0.77, 3.81) | |
Stage IV | 173 (16.2) | 1.00 | 1.00 | |||
Next appointment record | 1089 | |||||
Yes | 784 (72.0) | 1.00 | 1.00 | |||
No | 305 (28.0) | 173.30 | (99.25, 302.61)* | 241.39 | (119.90, 485.97)* | |